Articles related to DEPRESSION

A study of nearly 850 patients diagnosed with MDD examined the interrelationship between response rates on several outcome domains and their association with patients’ global rating of improvement.

Older adults using digital communications technology like email and video calls had higher levels of depression and anxiety about COVID-19. One explanation is that those who experiencing feelings of depression and anxiety were more likely to use digital tools. But another plausible explanation is that the digital technologies used were not well suited to older adults, possibly fueling their depression and anxiety.

The authors describe the case as well as the science around TRD and ketamine-assisted psychotherapy (KAP), explore the patient’s patterns of self-criticism and its impact on his depression and help-seeking, and their approach to KAP. This case report and review represents an “excellent example of how using different therapeutic frameworks is essential in the conceptualization and treatment of TRD.”

Aripiprazole supplementation of existing antidepressants in older adults with treatment-resistant depression significantly improved wellbeing over 10 weeks compared to switching to bupropion, and it was also associated with a numerically higher incidence of remission. Changes in wellbeing and the occurrence of remission with lithium augmentation or a switch to nortriptyline were comparable among patients in whom augmentation or a switch to bupropion failed.

The study included 186 patients who had recently been diagnosed with advanced lung cancer (Stage IV). Investigators were curious about the relationship between depression levels and systemic inflammation ratio (SIR) biomarker levels at diagnosis. SIRs are made up of three biomarkers that are linked to inflammation in the body, which has been linked to lower survival rates. All participants also filled out a depression questionnaire. According to the findings, 35% of patients had moderate to severe depressive symptoms.

The study enrolled 581 adult outpatients with DSM-5-diagnosed MDD, HDRS-17>=22, and >=32 on the Montgomery-Asberg Depression Rating Scale. Patients were randomly assigned to receive zuranolone 20 mg, 30 mg, or placebo for 14 days, followed by an observation period (days 15-42) and an extended follow-up period (days 43–182). The primary endpoint in HDRS-17 at day 15 was change from baseline (CFB). MOUNTAIN did not meet its primary endpoint, but there were significant rapid improvements in depressive symptoms with zuranolone 30 mg at days 3, 8, and 12, and it was generally well tolerated in patients with MDD.